Nektar Therapeutics NKTR
Nektar Therapeutics (Nasdaq: NKTR) is an immunology/inflammation drug developer. Its lead program, rezpegaldesleukin (REZPEG), is in Phase 3 for moderate-to-severe atopic dermatitis. Its next catalyst on record is rezpegaldesleukin: Initiate global registrational ZENITH-AA-1 trial in alopecia areata (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rezpegaldesleukin — Initiate global registrational ZENITH-AA-1 trial in alopecia areata (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rezpegaldesleukin - ZENITH AD-1/AD-2 (Phase 3 initiated July 2026) | moderate-to-severe atopic dermatitis | protein/peptide | Phase 3 |
| rezpegaldesleukin - Phase 2b REZOLVE-AA | severe-to-very-severe alopecia areata | protein/peptide | Phase 2 |
| rezpegaldesleukin - Phase 2 (TrialNet, NIH-funded) | new-onset stage 3 type 1 diabetes | protein/peptide | Phase 2 |
| NKTR-255 (IL-15 pathway agonist) | oncology (seeking partner) | biologic-other | Phase 2 |
| NKTR-0165 (TNFR2 agonist antibody) | ulcerative colitis, multiple sclerosis, vitiligo | antibody | Pre-clinical |
| NKTR-0166 (TNFR2 agonist/antagonist bispecific) | rheumatic disorders | antibody | Pre-clinical |
Recent results and decisions
- Oct 1, 2026positive REZOLVE-AA 52-week treatment cohort: 63% (5/8) of SALT≤20 responders maintained response at 6 months off treatment, and 48% of completers maintained week-52 SALT score; no new safety signals.
During the 6 Month Off-Treatment Period, 41% of Patients Achieved Deeper Responses and an Additional 22% Maintained Hair Regrowth
Filing - Apr 20, 2026positive 52-week extension: 29% (18 ug/kg) and 31% (24 ug/kg) of extension patients achieved new SALT<=20 from week 36 to 52; SALT<=30 at week 52 was 30.2% and 35.0% vs 8.4% placebo (exploratory p=0.023); 94% completed extension, safety consistent.
29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment
Filing - Feb 10, 2026positive All monthly (Q4W) and quarterly (Q12W) maintenance arms maintained responses through week 52; EASI-75 maintained by 67-92% of week-16 responders across arms.
All Monthly and Quarterly Arms Demonstrated Durability of Responses Over 36 Weeks of Maintenance Dosing Following Induction
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.